21-09-2026 20:14 via prnewswire.com

JumpCloud Channel Program Manager Selected for CRN's 100 People You Don't Know But Should List

LOUISVILLE, Colo., Sept. 21, 2026 /PRNewswire/ -- JumpCloud Inc. today announced that CRN from The Channel Company, named Ashok Murali to its 2026 "100 People You Don't Know But Should" list. As Senior Program Manager of Global Channel Partnerships, Murali landed a spot on this year's...
Read more »

PR Public relations news



Immunoassay Market to Reach US$ 47.5 Bn by 2031, Growing at 6% CAGR: New Report by Wissen Research
Immunoassay Market to Reach US$ 47.5 Bn by 2031, Growing at 6% CAGR: New Report by Wissen Research
Arizona Voters Want Elected Leaders to Take Action to Improve Public Education
Arizona Voters Want Elected Leaders to Take Action to Improve Public Education
In HelloNation, Personal Injury Law Expert John Wright of Rochester, NY, Explains When to give a Recorded Statement After a crash
In HelloNation, Personal Injury Law Expert John Wright of Rochester, NY, Explains When to give a Recorded Statement After a crash
Real Estate Expert Kim Odegard Explains How to Prioritize Home Repairs Before Selling in HelloNation
Real Estate Expert Kim Odegard Explains How to Prioritize Home Repairs Before Selling in HelloNation
ALAR Stockholder Reminder - Investors with Significant Losses in Alarum Technologies Ltd. Should Contact Robbins LLP for Information on Recovering Their Losses Before the October 5, 2026 Lead Plaintiff Deadline
ALAR Stockholder Reminder - Investors with Significant Losses in Alarum Technologies Ltd. Should Contact Robbins LLP for Information on Recovering Their Losses Before the October 5, 2026 Lead Plaintiff Deadline
BABA Stockholders: Robbins LLP Reminds Alibaba Group Holding Limited Stockholders with Large Losses to Seek Information About Leading the Class Action Before the October 5, 2026 Deadline
BABA Stockholders: Robbins LLP Reminds Alibaba Group Holding Limited Stockholders with Large Losses to Seek Information About Leading the Class Action Before the October 5, 2026 Deadline
SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline
SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline
SMAR Lead Plaintiff Deadline: Robbins LLP Encourages Sellers of Smartsheet Inc. Stock to Contact the Firm Before October 5, 2026 for Information About Leading the Class Action
SMAR Lead Plaintiff Deadline: Robbins LLP Encourages Sellers of Smartsheet Inc. Stock to Contact the Firm Before October 5, 2026 for Information About Leading the Class Action
Pure Michigan Welcomes Fall, Embraces the Magic of the Season
Pure Michigan Welcomes Fall, Embraces the Magic of the Season
La leyenda del Manchester United Louis Saha se unirá al panel de ponentes de Bahrain Fintech Forward 2026
La leyenda del Manchester United Louis Saha se unirá al panel de ponentes de Bahrain Fintech Forward 2026
Fannie Mae Announces Winners of its Latest Non-Performing Loan Sale
Fannie Mae Announces Winners of its Latest Non-Performing Loan Sale
ARDX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Ardelyx, Inc.
ARDX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Ardelyx, Inc.
Maggie Frerejean-Taittinger Nominated for Wine Enthusiast's 2026 Innovator of the Year Award for French Bloom's leading role in the evolution of the non-alcoholic landscape
Maggie Frerejean-Taittinger Nominated for Wine Enthusiast's 2026 Innovator of the Year Award for French Bloom's leading role in the evolution of the non-alcoholic landscape
Menarini Group und NewAmsterdam Pharma erhalten von der Europäischen Kommission die Zulassung für Ubeslo® (Obicetrapib als Monotherapie) und Evlarco® (Fixkombination aus Obicetrapib und Ezetimib)
Menarini Group und NewAmsterdam Pharma erhalten von der Europäischen Kommission die Zulassung für Ubeslo® (Obicetrapib als Monotherapie) und Evlarco® (Fixkombination aus Obicetrapib und Ezetimib)
Desktop versie